⌕
Trevi Therapeutics · TRVI · Nasdaq
Tenet 53 · Mixed
Compare
$13.51+1.66%At closeTenet 53 · Mixed
$13.51+0.22 (+1.66%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Trevi Therapeutics (TRVI) Institutional Ownership

13F filers reported holding 58.2% of Trevi Therapeutics (TRVI) shares as of Sep 30, 2026, across 153 filers.

Sources Ownership filingsQuarter ended How we compute thisNot investment advice
Held by 13F filers
58.2%
Sep 30, 2026
13F filers
153
quarter ended Sep 30, 2026
13F value
$1.2B
82.9M shares
Quarter's fund flow
Mild accumulation
20 new · 15 closed

Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.

13F fund flowQuarter ended Sep 30, 2026: more funds added or entered than trimmed or exited, mild accumulation (20 new · 67 increased · 36 reduced · 15 closed · 15 unchanged or with no prior quarter on file). Flows at this scale move slowly; treat as context. These positions are 49 days old; the 45-day figure often quoted is the SEC filing deadline after quarter-end, not the age of the data. The counts above compare each filer’s position with its own previous 13F. The change in the number of filers and in the ownership share is not shown: the filings we read hold only each filer’s latest 13F, so there is no earlier quarter of the same filers to compare against. That is a limit of the source, not a statement about this company.
Basis: shares reported by 153 13F filers for Sep 30, 2026, over shares outstanding implied from the current quote, measured 49 days apart. It measures the ownership we have filings for, not total institutional ownership, and it moves with the share count between filings.
routine sells are usually compensation mechanics; open-market buys are the rarer signal. Rows labelled with another security are the derivative leg of a vest or exercise, not share sales
DateNameRoleTypeSharesPriceSEC filing
Jun 3, 2026Mathers Edward TdirectorAcquired · Grant / award35,000Nonstatutory Stock Option (right to buy)—↗
Jun 3, 2026Meeker David PdirectorAcquired · Grant / award35,000Nonstatutory Stock Option (right to buy)—↗
Jun 3, 2026VANLENT ANNEdirectorAcquired · Grant / award35,000Nonstatutory Stock Option (right to buy)—↗
Jun 3, 2026Colangelo DominickdirectorAcquired · Grant / award35,000Nonstatutory Stock Option (right to buy)—↗
Jun 3, 2026Heffernan Michael ThomasdirectorAcquired · Grant / award35,000Nonstatutory Stock Option (right to buy)—↗
Feb 19, 2026Cassella James VChief Development OfficerAcquired · Grant / award215,000Stock Option (right to buy)—↗
Feb 19, 2026Galletta ChristopherSee RemarksAcquired · Grant / award35,000Stock Option (right to buy)—↗
Feb 19, 2026SCIASCIA THOMASChief Scientific OfficerAcquired · Grant / award85,000Stock Option (right to buy)—↗
Feb 19, 2026GOOD JENNIFER LPresident & CEOAcquired · Grant / award675,000Stock Option (right to buy)—↗
Feb 19, 2026Simon FarrellChief Commercial OfficerAcquired · Grant / award160,000Stock Option (right to buy)—↗
Jan 8, 2026HASTINGS DAVID CChief Financial OfficerAcquired · Grant / award375,000Stock Option (right to buy)—↗
Dec 2, 2025Galletta ChristopherSee RemarksAcquired · Option exercise4,225$0.51↗
Dec 2, 2025Galletta ChristopherSee RemarksDisposed · Option exercise4,225Stock Option (right to buy)—↗
Jun 11, 2025Mathers Edward TdirectorAcquired · Grant / award45,000Nonstatutory Stock Option (right to buy)—↗
Jun 11, 2025Colangelo DominickdirectorAcquired · Grant / award45,000Nonstatutory Stock Option (right to buy)—↗
Jun 11, 2025Heffernan Michael ThomasdirectorAcquired · Grant / award45,000Nonstatutory Stock Option (right to buy)—↗
Jun 11, 2025VANLENT ANNEdirectorAcquired · Grant / award45,000Nonstatutory Stock Option (right to buy)—↗
Jun 11, 2025Meeker David PdirectorAcquired · Grant / award45,000Nonstatutory Stock Option (right to buy)—↗
May 31, 2025Galletta ChristopherSee RemarksAcquired · Grant / award8,550Performance Stock Option (right to buy)—↗
May 31, 2025SCIASCIA THOMASChief Scientific OfficerAcquired · Grant / award60,000Performance Stock Option (right to buy)—↗

* Holdings as reported for Sep 30, 2026, 49 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.

** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.

How much of Trevi Therapeutics do institutions hold?

13F filers reported holding 58.2% of Trevi Therapeutics' shares as of Sep 30, 2026, across 153 filers.

How many 13F filers hold Trevi Therapeutics?

Trevi Therapeutics was held by 153 13F filers as of Sep 30, 2026.

Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.